Literature DB >> 21946457

An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study.

Fernando Perez-Ruiz1, Loreto Carmona, Maria Jesús García Yébenes, Eliseo Pascual, Eugenio de Miguel, Inmaculada Ureña, Miguel A González-Gay.   

Abstract

OBJECTIVE: The objectives of the study were to evaluate the rate of variability in diagnosis and treatment of the patients with gout in the rheumatology setting and to estimate the rate of adjustment to the European League Against Rheumatism recommendations as a key step to improve the quality of care in gout.
METHODS: The GEMA (Gout Evaluation and MAnagement) study is a cross-sectional audit in which 803 files of patients with an International Classification of Diseases code of gout were randomly chosen from 41 rheumatology units. The data collected regarded the clinical management of gout. Indicators based on the European League Against Rheumatism recommendations were created, and information on the fulfillment of the recommendations was retrieved. The mean adjustment and 95% confidence interval (CI) were estimated for each recommendation.
RESULTS: Patients from whose files information was retrieved were very representative of gout (94% were men, with a mean age of 60 years, 43% obese, 62% hypertensive, more than 25% with tophaceous gout, 61% hyperlipidemic). A diagnosis based on the observation of monosodium urate crystals on the microscope had been made in only 26%; thus, the adjustment to diagnostic recommendations was low, 26.0% (95% CI, 18.9%-33.1%). The adjustment to the recommendations on evaluating comorbidity was 50.6% (95% CI, 46.6%-54.5%). Mean adjustment to recommendations on management, in general, was better, especially those regarding acute flares (100%), and lifestyle changes, with 71.4% (95% CI, 63.7%-79.1%) with treatment using urate-lowering drugs could be improved (mean adjustment, 52.1% [95% CI, 43.1-61.1]).
CONCLUSIONS: Overall, implementation of clinical care in gout should be put on further attention to diagnosis, time-consuming evaluation of comorbidities, and long-term control of serum urate levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946457     DOI: 10.1097/RHU.0b013e3182314d40

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  11 in total

1.  Use of systemic glucocorticoids in patients with psoriatic arthritis by Argentinian and other Latin-American rheumatologists.

Authors:  Carolina Aimo; Vanesa Laura Cosentino; Gabriel Sequeira; Eduardo Kerzberg
Journal:  Rheumatol Int       Date:  2019-03-04       Impact factor: 2.631

2.  Reply: Gout treatment--more tablets might be needed.

Authors:  Fernando Perez-Ruiz; Ana Maria Herrero-Beites
Journal:  Nat Rev Rheumatol       Date:  2014-01-28       Impact factor: 20.543

3.  Improvement in Diagnosis and Treat-to-Target Management of Hyperuricemia in Gout: Results from the GEMA-2 Transversal Study on Practice.

Authors:  Fernando Perez Ruiz; Carlos A Sanchez-Piedra; Jesus T Sanchez-Costa; Mariano Andrés; Cesar Diaz-Torne; Mercedes Jimenez-Palop; Eugenio De Miguel; Carmen Moragues; Francisca Sivera
Journal:  Rheumatol Ther       Date:  2017-12-04

4.  Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis.

Authors:  Robert Morlock; Pierre Chevalier; Laura Horne; Javier Nuevo; Chris Storgard; Lalitha Aiyer; Dionne M Hines; Xavier Ansolabehere; Fredrik Nyberg
Journal:  Rheumatol Ther       Date:  2016-05-25

Review 5.  Dietary supplements for chronic gout.

Authors:  Mariano Andrés; Francisca Sivera; Rachelle Buchbinder; Jordi Pardo Pardo; Loreto Carmona
Journal:  Cochrane Database Syst Rev       Date:  2021-11-12

6.  [Austrian 3e-recommendations for diagnosis and management of gout 2013].

Authors:  Judith Sautner; Johann Gruber; Manfred Herold; Jochen Zwerina; Burkhard F Leeb
Journal:  Wien Klin Wochenschr       Date:  2013-12-03       Impact factor: 1.704

7.  An in silico method to identify computer-based protocols worthy of clinical study: An insulin infusion protocol use case.

Authors:  Anthony F Wong; Ulrike Pielmeier; Peter J Haug; Steen Andreassen; Alan H Morris
Journal:  J Am Med Inform Assoc       Date:  2015-07-30       Impact factor: 4.497

8.  Treatment with Allopurinol is Associated with Lower Risk of Acute Kidney Injury in Patients with Gout: A Retrospective Analysis of a Nested Cohort.

Authors:  Fernando Perez-Ruiz
Journal:  Rheumatol Ther       Date:  2017-09-27

9.  Serum uric acid levels are associated with a high risk of rapid chronic kidney disease progression among patients with type 2 diabetes: a prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 12)].

Authors:  Hirohito Kuwata; Shintaro Okamura; Yasuaki Hayashino; Hitoshi Ishii; Satoru Tsujii
Journal:  Diabetol Int       Date:  2016-02-03

10.  Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.

Authors:  Francisca Sivera; Mariano Andrés; Loreto Carmona; Alison S R Kydd; John Moi; Rakhi Seth; Melonie Sriranganathan; Caroline van Durme; Irene van Echteld; Ophir Vinik; Mihir D Wechalekar; Daniel Aletaha; Claire Bombardier; Rachelle Buchbinder; Christopher J Edwards; Robert B Landewé; Johannes W Bijlsma; Jaime C Branco; Rubén Burgos-Vargas; Anca I Catrina; Dirk Elewaut; Antonio J L Ferrari; Patrick Kiely; Burkhard F Leeb; Carlomaurizio Montecucco; Ulf Müller-Ladner; Mikkel Ostergaard; Jane Zochling; Louise Falzon; Désirée M van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-07-18       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.